• Clinical experience with Septolete plus products in the treatment of sore throat
To content

Clinical experience with Septolete plus products in the treatment of sore throat

SOVREMENNAYA PEDIATRIYA. 2014.8(64):60–64

Clinical experience with Septolete plus products in the treatment of sore throat

Kosir P.

 

Abstract. A sore throat is a common complaint among children, adolescents and adults. It refers to a painful sensation localised to the pharynx and surrounding anatomy and can be a symptom of a disease process not directly linked to the pharynx (e.g. cold or flu). The treatment of sore throat depends upon the cause. Due to the predominantly viral cause, antibiotics have only a marginal benefit as they do not improve throat pain and are thus not recommended. An alternative to systemic antibiotic therapy in such cases is the use of oral antiseptics, which are often combined with local anesthetics to relieve pain and thus alleviate subjective discomfort. Septolete plus products contain a broad-spectrum antiseptic, cetylpyridinium chloride (CPC), and the local anesthetic benzocaine. In clinical studies Septolete plus has demonstrated high efficacy and good tolerability in the treatment of sore throat. The analgesic effect of Septolete plus lozenges started in fifteen minutes and lasted for two to three hours. Complete healing or improvement of the signs and symptoms of the disease was observed in 90–100% of the patients treated with Septolete plus lozenges and 87.5% of the patients treated with Septolete plus oromucosal spray. Secondary infections occurred in not more than 3.8% of the patients treated with lozenges. Additionally, a considerable reduction in the microorganism count was demonstrated for Septolete plus lozenges.

Key words: pharyngitis, antiseptics, local anesthetics, cetylpyridinium chloride, benzocaine

 

References:

1. Bisino A. Acute pharyngitis. The New England Journal of Medicine. 2011; Vol. 344, No. 3; 205—11.

2. Hannaford P.C., Simpson J.A., Bisset A.F., Davis A., McKerrow W., Mills R. The prevalence of ear, nose and throat problems in the community:results from a national cross_sectional postal survey in Scotland. Fam Pract 2005, 22: 227—33.

3. Clements A.D. Pharyngitis, laryngitis and epiglottitis. In: Cohen J, Powderly WG. Infectious diseases. Vol 1. London: Harcourt Publishers Ltd, 1999: 341—7.

4. Hughes W. Candidiasis. In: Feign R.D., Cherry D.J. Textbook of pediatric infectious diseases. Vol 2. Philadelphia: W. B. Saunders Company, 1992: 1907—11.

5. Addey D. Incidence, causes, severity and treatment of throat discomfort: a four-region online questionnaire survey. BMC Ear Nose Throat Disord 2012.

6. Wunderer H. Mund- und Rachentherapeutika. DAZ. 1986; 126 (42): 2281—92.

7. Akpan A. Oral candidiasis. Postgrad Med J 2002; 78: 455—9.

8. Little P.S., Wiliamson I. Contraversis in management: Are antibiotics appropriate for sore throats? Costs outweigh the benefits. BMJ 1994; 309 (6960): 1010—1.

9. Little P.S., Wiliamson I., Warner G. et al. Open randomised trial of prescribing strategies in managing sore throat. Practitioner 1981; 225 (1352): 234—9.

10. Konschal U. Antiseptische Lokaltherapeutika als eigenstandige Therapie HNO-arztlich gesehen. Therapiewoche. 1977; 27: 7732—9.

11. Meier E. Schluckbeschwerden, Halsschmerzen, Heiserkeit. Apotheker Journal. 1990; 12: 26–32.

12. Weber R. Mund- und Rachentherapeutika. PTA heute. 1987; 1 (4): 108—11.

13. Sweetman S. Martindale: The Complete Drug Reference: Cetylpyridinium chloride. London: Pharmaceutical Press. Electronic version, 2008.

14. Kramer A. Hagers Handbuch der Pharmazeutischen Praxis, 5 Aufl.

Bd7 Springer-Verlag, Berlin-Heidelberg 1990.

15. Merianos J.J. Quaternary ammonium antimicrobial compounds. In: Block SS: Disinfection, Sterilisation and Preservation. 4th ed. Philadelphia, London: Lea & Febiger. 1991; 225—55.

16. Drugdex Drug Evaluations: Benzocaine. Micromedex® Healthcare Series: MICROMEDEX, Inc., Englewood, Colorado, Vol 138. Expires 12/2008.

17. Strichartz G. Molecular mechanism of nerve block by local anesthetics. Anesthesiology 1976; 15 (1): 421—41.

18. Bulc M. Final report. Monitoring of efficacy and safety of the medicinal product Septolete plus in patients with pharyngeal pain. Data on file. Krka, d. d., Novo mesto, Slovenia, 2003.

19. Rjazancev S.V., Timchuk L.E. Final report. Study of efficacy and safety of the product Septolete plus in patients with a sore throat. Russia, S. Petersburg. Data on file. Krka, d. d., Novo mesto, Slovenia, 2005.

20. Final report. Post-authorisation non-interventional study of the efficacy and safety of the medicinal product Neoseptolete with anesthetic effect, orm. pas., Czech Republic. Data on file. Krka, d. d., Novo mesto, Slovenia, 2007.

21. Zabolotny D.I. Final report. Open-labeled non-comparative uncontrolled study of the efficacy and safety of Septolete plus in patients with a sore throat, Ukraine. Data on file. Krka, d. d., Novo mesto, Slovenia, 2007.

22. Zabolotnyy D.I. et al. Treatment of chronic pharyngitis at the stage of aggravation: clinical, immunological and microbiological aspects. Zdorovja Ukraini. The Medical Journal 2007; 19 (176): 1—3.

23. Final report. A comparative study of the efficacy and safety of Septolete plus oromucosal spray 1.5 mg + 0.3 mg/dose (cetylpiridinium chloride/benzocaine) in subjects with sore throat associated with upper respiratory tract infections, including tonsillopharyngitis: a comparison with the reference product TheraFlu LAR spray; Phase III study. Data on file. Krka, d. d., Novo mesto, Slovenia, 2013.